Comparison of atrial fibrillation risk factors between sexes.

<p>Comparison of atrial fibrillation risk factors between sexes.</p

Baseline characteristics of study patients with non-valvular atrial fibrillation^*.

<p>Baseline characteristics of study patients with non-valvular atrial fibrillation^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175405#t001fn002" target="_blank">*</a>}.</p

Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).

<p>Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).</p

Comparison of differences in CHADS₂ with warfarin and antiplatelet therapy between sexes (n = 1776).

<p>Comparison of differences in CHADS₂ with warfarin and antiplatelet therapy between sexes (n = 1776).</p

Treatment on admission and at discharge of the study cohort stratified according to gender (n = 7930).

<p>Figures in parentheses are percentages. Abbreviations: BB, beta-blockers; CCB, calcium channel blockers; ACE, angiotensin-converting enzyme inhibitors; AIIRB, angiotensin II receptor blockers; OHA, oral hypoglycemic agents; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft.</p

Baseline characteristics of patients stratified by gender (n = 7930).

<p>Figures in parentheses are percentages and continuous variables are shown as mean±SD.</p><p>Abbreviations: SD, standard deviation; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CHF, congestive heart failure; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.</p>*<p>Killip class (scale I–IV) a system used to stratify the severity of left ventricular dysfunction and determines clinical status of patients post myocardial infarction (MI).</p><p>Killip classification:</p><p>Class 1: No rales, no 3rd heart sound.</p><p>Class 2: Rales in <1/2 lung field or presence of a 3rd heart sound.</p><p>Class 3: Rales in >1/2 lung field–pulmonary edema.</p><p>Class 4: Cardiogenic shock–determined clinically.</p

In-hospital outcomes and 1-month and 1-year post discharge mortality of the study cohort by gender (n = 7930).

<p>Figures in parentheses are percentages.</p

Variables in model IV, and their effects on mortality.

<p>ORs for variables with multiple levels (country, diagnosis, and predominant symptoms) are not shown. The variables that were dropped out of the multivariable logistic regression using the stepwise-backward elimination method included: smoking, BMI, history of hypertension and hyperlipidaemia, clopidogrel as discharge medication, PCI, and CABG.</p>*<p>Predominant presenting symptoms includes: ischemic type chest pain, atypical chest pain, dyspnea, fatigue, loss of consciousness, cardiac arrest/aborted sudden death, palpitation and other symptoms.</p><p>Abbreviations: OR, odds ratio; CI, confidence interval; BB, beta-blockers; CCB, calcium channel blockers; ACE, angiotensin-converting enzyme inhibitors; AIIRB, angiotensin II receptor blockers.</p

Median time-line of events from symptoms-onset to the administration of reperfusion therapies (total ischemic time) in acute STEMI patients that arrived to the hospital by an emergency medical service (EMS) versus not (non-EMS).

<p>SO, symptoms-onset, FMC, first medical contact; ED, Emergency Department arrival, ECG, electrocardiogram; TT/PPCI, thrombolytic therapy/primary percutaneous coronary intervention.</p

Number of hospitals with percutaneous coronary intervention capability (PCI H.) versus without (Non-PCI H.) that enrolled acute STEMI patients in the study per each Arabian Gulf country.

<p>Number of hospitals with percutaneous coronary intervention capability (PCI H.) versus without (Non-PCI H.) that enrolled acute STEMI patients in the study per each Arabian Gulf country.</p